managing and treating crs, neurological toxicity and cytopenias associated with car-t therapy
Published 1 year ago • 113 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
8:37
safety and efficacy of cd7-targeted car-t therapy in patients with r/r t-all and t-lbl
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
2:16
evaluating the safety and efficacy of novel anti-cd7 universal car-t therapy in r/r t-all and t-lbl
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
3:43
the future of car-t therapy
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
1:08
the benefits of car-t therapy in 2l over 3l in r/r dlbcl
-
1:10
tackling resistance to car-t therapy across hematological malignancies
-
2:41
cell avidity as a predictor of t-cell efficacy
-
1:43
management of car-t related side effects
-
2:20
the risk of t-cell malignancies associated with car t-cell therapy
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
3:19
car-t and neurotoxicity: frequency and management
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
1:02
the use of car-t cell products in a real-world setting
-
4:17
novel car t-cell therapies for hematological malignancies: exploring new targets
-
2:05
the cost-effectiveness of car t-cell therapy